1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Regeneron Pharmaceuticals Inc (REGN) Files 10-K for the Fiscal Year Ended on December 31, 2018

February 07, 2019 | About:

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron Pharmaceuticals Inc has a market cap of $43.99 billion; its shares were traded at around $406.46 with a P/E ratio of 25.98 and P/S ratio of 7.34. Regeneron Pharmaceuticals Inc had annual average EBITDA growth of 31.70% over the past five years.

For the last quarter Regeneron Pharmaceuticals Inc reported a revenue of $1.9 billion, compared with the revenue of $1.6 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $6.7 billion, an increase of 14.3% from last year. For the last five years Regeneron Pharmaceuticals Inc had an average revenue growth rate of 26.3% a year. The Regeneron Pharmaceuticals Inc enjoyed an operating margin of 37.77%, compared with the operating margin of 35.41% a year before. The 10-year historical median operating margin of Regeneron Pharmaceuticals Inc is 28.30%. The profitability rank of the company is 9 (out of 10).

At the current stock price of $406.46, Regeneron Pharmaceuticals Inc is traded at 25% discount to its historical median P/S valuation band of $542.10. The P/S ratio of the stock is 7.34, while the historical median P/S ratio is 9.80. The stock gained 21.47% during the past 12 months.

Directors and Officers Recent Trades:

  • Director Joseph L Goldstein sold 1,791 shares of REGN stock on 01/10/2019 at the average price of $410. The price of the stock has decreased by 0.86% since.

For the complete 20-year historical financial data of REGN, click here.


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by insider


User Generated Screeners


jbucheliHighly Leveraged
jbostwickosv growth 50% gpa MidCAP Best
crmaasteste2
mgr1929Start%20screening%20here
pbarker46Start screening here
tnavasardianNA high yield
shahrukhshahzadZULU
peterc123Netnet 2019
5dmeyerJoel Greenblatt screen
ricardo9959Parecida DIS v2
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK